Zheng Zhiyao, Liu Chenglong, Mou Siqi, Li Junsheng, He Qiheng, Liu Wei, Zhang Bojian, Zhao Zhikang, Sun Wei, Zhang Qian, Wang Rong, Zhang Yan, Zhang Dong, Ge Peicong
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Research Unit of Accurate Diagnosis, Treatment, and Translational Medicine of Brain Tumors (No.2019RU011), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China; Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; China National Clinical Research Center for Neurological Diseases, Beijing, 100070, China.
Clin Nutr. 2025 Apr;47:83-93. doi: 10.1016/j.clnu.2025.02.008. Epub 2025 Feb 11.
Taurine has been proven to play a significant role in cardiovascular and cerebrovascular diseases, but its relationship with moyamoya disease (MMD) remains unclear. This study aims to investigate the association between serum taurine levels and long-term adverse cerebrovascular events in patients with MMD after revascularization.
This study involved 352 patients with MMD, from whom comprehensive clinical data and blood samples were collected. Serum taurine levels were measured using liquid chromatography-tandem mass spectrometry, and the relationship between serum taurine concentration and various blood indices was evaluated. Cerebrovascular adverse events included transient ischemic attack, ischemic stroke, and hemorrhagic stroke. Taurine, analyzed as a continuous variable, was found to predict a cut-off for postoperative cerebrovascular adverse events in MMD patients at 842.52 μmol/L. The impact of serum taurine levels on the risk of cerebrovascular events was analyzed using Kaplan-Meier (KM) curves, and univariate and multivariate Cox regression analyses were performed to identify predictive factors for postoperative prognosis.
Grouping MMD patients by serum taurine levels revealed that higher taurine levels were significantly associated with a lower proportion of hemorrhagic MMD (p = 0.044). Compared with ischemic MMD, patients with hemorrhagic MMD had lower taurine concentrations (p = 0.005). KM curves showed that the incidence of postoperative cerebrovascular adverse events in the high taurine group was significantly lower than in the low taurine group (p = 0.026). Univariate Cox regression analysis indicated that higher taurine concentrations significantly reduced the risk of postoperative cerebrovascular adverse events (Hazard Ratio [HR] = 0.334, 95 % Confidence Interval [CI] = 0.121-0.923, p = 0.035). Furthermore, the multivariate Cox regression model confirmed that taurine level is an independent predictor of long-term adverse cerebrovascular events, with the high concentration group showing a significantly reduced risk.
Low serum taurine levels are associated with a higher risk of long-term adverse cerebrovascular events following MMD revascularization. This suggests the significant potential of serum taurine as a prognostic biomarker for postoperative outcomes.
URL: https://www.chictr.org.cn/. Unique identifier: ChiCTR2200061889.
已证实牛磺酸在心血管和脑血管疾病中发挥重要作用，但其与烟雾病（MMD）的关系仍不清楚。本研究旨在探讨MMD患者血清牛磺酸水平与血运重建术后长期不良脑血管事件之间的关联。
本研究纳入352例MMD患者，收集其全面的临床资料和血样。采用液相色谱-串联质谱法测定血清牛磺酸水平，并评估血清牛磺酸浓度与各项血液指标之间的关系。脑血管不良事件包括短暂性脑缺血发作、缺血性卒中和出血性卒中。牛磺酸作为连续变量进行分析，发现其可预测MMD患者术后脑血管不良事件的临界值为842.52 μmol/L。采用Kaplan-Meier（KM）曲线分析血清牛磺酸水平对脑血管事件风险的影响，并进行单因素和多因素Cox回归分析以确定术后预后的预测因素。
按血清牛磺酸水平对MMD患者进行分组显示，较高的牛磺酸水平与出血性MMD的比例较低显著相关（p = 0.044）。与缺血性MMD相比，出血性MMD患者的牛磺酸浓度较低（p = 0.005）。KM曲线显示，高牛磺酸组术后脑血管不良事件的发生率显著低于低牛磺酸组（p = 0.026）。单因素Cox回归分析表明，较高的牛磺酸浓度显著降低了术后脑血管不良事件的风险（风险比[HR]=0.334，95%置信区间[CI]=0.121-0.923，p = 0.035）。此外，多因素Cox回归模型证实，牛磺酸水平是长期不良脑血管事件的独立预测因子，高浓度组风险显著降低。
血清牛磺酸水平低与MMD血运重建术后长期不良脑血管事件的风险较高相关。这表明血清牛磺酸作为术后预后生物标志物具有巨大潜力。
